176 related articles for article (PubMed ID: 26714675)
1. A retrospective analysis of treatment-related hospitalization costs of pediatric, adolescent, and young adult acute lymphoblastic leukemia.
Kaul S; Korgenski EK; Ying J; Ng CF; Smits-Seemann RR; Nelson RE; Andrews S; Raetz E; Fluchel M; Lemons R; Kirchhoff AC
Cancer Med; 2016 Feb; 5(2):221-9. PubMed ID: 26714675
[TBL] [Abstract][Full Text] [Related]
2. Hospitalization rate and costs in acute lymphoblastic leukemia of childhood in a low-income group: Financial impact in Northeast Mexico.
Jaime-Pérez JC; Fernández LT; Jiménez-Castillo RA; Colunga-Pedraza JE; Padilla-Medina JR; Mancías-Guerra C; Gómez-Almaguer D
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28598592
[TBL] [Abstract][Full Text] [Related]
3. ReCAP: Gaps in Insurance Coverage for Pediatric Patients With Acute Lymphoblastic Leukemia.
Smits-Seemann RR; Kaul S; Hersh AO; Fluchel MN; Boucher KM; Kirchhoff AC; Smits-Seemann RR; Kaul S; Hersh AO; Fluchel MN; Boucher KM; Kirchhoff AC
J Oncol Pract; 2016 Feb; 12(2):175-6; e207-14. PubMed ID: 26420890
[TBL] [Abstract][Full Text] [Related]
4. Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials.
Bennett CL; Stinson TJ; Lane D; Amylon M; Land VJ; Laver JH
Med Pediatr Oncol; 2000 Feb; 34(2):92-6. PubMed ID: 10657867
[TBL] [Abstract][Full Text] [Related]
5. Health care utilisation and costs associated with different treatment protocols for newly diagnosed childhood acute lymphoblastic leukaemia: A population-based study in Ontario, Canada.
Gupta S; Sutradhar R; Li Q; Athale U; Bassal M; Breakey V; Gibson PJ; Patel S; Silva M; Zabih V; Pechlivanoglou P; Pole JD; Mittmann N
Eur J Cancer; 2021 Jul; 151():126-135. PubMed ID: 33979728
[TBL] [Abstract][Full Text] [Related]
6. Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232.
DiNofia AM; Seif AE; Devidas M; Li Y; Hall M; Huang YV; Cahen V; Hunger SP; Winick NJ; Carroll WL; Fisher BT; Larsen EC; Aplenc R
Cancer Med; 2018 Jan; 7(1):3-12. PubMed ID: 29274118
[TBL] [Abstract][Full Text] [Related]
7. Volume-Outcome Relationships in Pediatric Acute Lymphoblastic Leukemia: Association Between Hospital Pediatric and Pediatric Oncology Volume With Mortality and Intensive Care Resources During Initial Therapy.
Wilkes JJ; Hennessy S; Xiao R; Rheingold S; Seif AE; Huang YS; Vendetti N; Li Y; Bagatell R; Aplenc R; Fisher BT
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):404-410.e1. PubMed ID: 27246140
[TBL] [Abstract][Full Text] [Related]
8. The Effects of Hospital Length of Stay on Readmissions for Children With Newly Diagnosed Acute Lymphoblastic Leukemia.
Wedekind MF; Dennis R; Sturm M; Koch T; Stanek J; O'Brien SH
J Pediatr Hematol Oncol; 2016 Jul; 38(5):329-33. PubMed ID: 26989914
[TBL] [Abstract][Full Text] [Related]
9. Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies.
Gaynon PS; Bostrom BC; Hutchinson RJ; Lange BJ; Nachman JB; Steinherz PG; Sensel MG; Lee MK; Stram DO; Sather HN
J Clin Oncol; 2001 Apr; 19(7):1916-25. PubMed ID: 11283123
[TBL] [Abstract][Full Text] [Related]
10. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia.
Pui CH; Boyett JM; Hughes WT; Rivera GK; Hancock ML; Sandlund JT; Synold T; Relling MV; Ribeiro RC; Crist WM; Evans WE
N Engl J Med; 1997 Jun; 336(25):1781-7. PubMed ID: 9187068
[TBL] [Abstract][Full Text] [Related]
11. ICU Admission in Children With Acute Lymphoblastic Leukemia in Sweden: Prevalence, Outcome, and Risk Factors.
Ranta S; Broman LM; Abrahamsson J; Berner J; Fläring U; Hed Myrberg I; Kalzén H; Karlsson L; Mellgren K; Nilsson A; Norén-Nyström U; Palle J; von Schewelov K; Svahn JE; Törnudd L; Heyman M; Harila-Saari A
Pediatr Crit Care Med; 2021 Dec; 22(12):1050-1060. PubMed ID: 34074998
[TBL] [Abstract][Full Text] [Related]
12. Burden of Influenza-Related Hospitalizations and Attributable Mortality in Pediatric Acute Lymphoblastic Leukemia.
Lee GE; Fisher BT; Xiao R; Coffin SE; Feemster K; Seif AE; Bagatell R; Li Y; Huang YS; Aplenc R
J Pediatric Infect Dis Soc; 2015 Dec; 4(4):290-6. PubMed ID: 26582867
[TBL] [Abstract][Full Text] [Related]
13. Burden of hospitalization in relapsed acute lymphoblastic leukemia.
Barlev A; Lin VW; Song X
Curr Med Res Opin; 2016 Jul; 32(7):1209-12. PubMed ID: 26960412
[TBL] [Abstract][Full Text] [Related]
14. Decreased Early Mortality in Young Adult Patients With Acute Lymphoblastic Leukemia Treated at Specialized Cancer Centers in California.
Alvarez EM; Malogolowkin M; Li Q; Brunson A; Pollock BH; Muffly L; Wun T; Keegan THM
J Oncol Pract; 2019 Apr; 15(4):e316-e327. PubMed ID: 30849003
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors for Readmission Following Febrile Neutropenia in Pediatric Oncology Patients.
McCormick M; Richardson T; Rapkin L; Kalpatthi R
J Pediatr Hematol Oncol; 2023 May; 45(4):e496-e501. PubMed ID: 36346651
[TBL] [Abstract][Full Text] [Related]
16. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
[TBL] [Abstract][Full Text] [Related]
17. Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review.
Dombret H; Thomas X; Chevallier P; Nivot E; Reitan J; Barber B; Barlev A; Mohty M
J Med Econ; 2016 Nov; 19(11):1034-1039. PubMed ID: 27207188
[TBL] [Abstract][Full Text] [Related]
18. Economic burden associated with adverse events of special interest in patients with relapsed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the United States.
Zhang X; Song X; Lopez-Gonzalez L; Jariwala-Parikh K; Cong Z
Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):573-580. PubMed ID: 29923428
[TBL] [Abstract][Full Text] [Related]
19. Retrospective chart review of hospitalizations and costs associated with the treatment of adults with Philadelphia-negative B-cell relapsed or refractory acute lymphoblastic leukemia in Belgium.
Maertens J; Graux C; Breems D; Havelange V; Wittnebel S; Strens D; Hoefkens C
Acta Clin Belg; 2017 Dec; 72(6):429-433. PubMed ID: 28406385
[TBL] [Abstract][Full Text] [Related]
20. Expenditures among young adults with acute lymphoblastic leukemia by site of care.
Wolfson JA; Bhatia S; Ginsberg J; Becker LK; Bernstein D; Henk HJ; Lyman GH; Nathan PC; Puccetti D; Wilkes JJ; Winestone LE; Kenzik KM
Cancer; 2021 Jun; 127(11):1901-1911. PubMed ID: 33465248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
